T. Rowe Price Associates
NARI

T. Rowe Price Associates’s Inari Medical, Inc. Common Stock NARI Stock Holding History

T. Rowe Price Associates’s Portfolio NARI Stock Details NARI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,288
Closed -$2.06M – 3094
2024
Q4 		$2.06M Sell
40,288
-130,154
-76% -$6.4M ﹤0.01% 1637
2024
Q3 		$7.03M Sell
170,442
-133,591
-44% -$6.41M ﹤0.01% 1210
2024
Q2 		$14.6M Sell
304,033
-69,314
-19% -$3.07M ﹤0.01% 1033
2024
Q1 		$17.9M Buy
373,347
+2,003
+0.5% +$107K ﹤0.01% 997
2023
Q4 		$24.1M Sell
371,344
-878,550
-70% -$52.9M ﹤0.01% 912
2023
Q3 		$81.7M Sell
1,249,894
-109,443
-8% -$6.89M 0.01% 551
2023
Q2 		$79M Sell
1,359,337
-504,479
-27% -$31.8M 0.01% 579
2023
Q1 		$115M Buy
1,863,816
+1,060,839
+132% +$63.7M 0.02% 486
2022
Q4 		$51M Buy
802,977
+139,929
+21% +$10.1M 0.01% 654
2022
Q3 		$48.2M Sell
663,048
-1,303,254
-66% -$97M 0.01% 657
2022
Q2 		$134M Buy
1,966,302
+356,309
+22% +$25.6M 0.02% 582
2022
Q1 		$146M Buy
1,609,993
+490,718
+44% +$40.2M 0.01% 625
2021
Q4 		$102M Buy
1,119,275
+241,112
+27% +$20.7M 0.01% 762
2021
Q3 		$71.2M Buy
878,163
+575,397
+190% +$48.3M 0.01% 889
2021
Q2 		$28.2M Sell
302,766
-269,128
-47% -$26.1M ﹤0.01% 1215
2021
Q1 		$61.2M Sell
571,894
-14,562
-2% -$1.51M 0.01% 930
2020
Q4 		$51.2M Sell
586,456
-2,403
-0.4% -$170K 0.01% 956
2020
Q3 		$40.6M Sell
588,859
-74,875
-11% -$4.81M ﹤0.01% 939
2020
Q2 		$32.2M Buy
+663,734
New +$31.7M ﹤0.01% 993

Other funds holding NARI

SA
SoundView Advisors Olympia, Washington $307M AUM 20.33% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $8.31B AUM 21.94% 1-Year Est. Return

T. Rowe Price Associates's NARI Position: Q1 2025 in Review

T. Rowe Price Associates sold out of Inari Medical, Inc. Common Stock (NARI) in Q1 2025, closing a stake of 40,288 shares — an estimated $2.06M sold.

T. Rowe Price Associates first reported a position in NARI in Q2 2020 and held it in 19 quarters. The position peaked at $146M in Q1 2022. 4 funds tracked by Wall St. Rank hold NARI as of Q1 2025.

  • T. Rowe Price Associates reported no remaining Inari Medical, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 40,288 Inari Medical, Inc. Common Stock shares in Q1 2025, an estimated $2.06M.
  • T. Rowe Price Associates first reported a position in Inari Medical, Inc. Common Stock in Q2 2020 and held it in 19 quarters.
  • T. Rowe Price Associates's Inari Medical, Inc. Common Stock position peaked at $146M in Q1 2022.
  • 4 funds tracked by Wall St. Rank held Inari Medical, Inc. Common Stock as of Q1 2025.

Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.